Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Vicarious Surgical Yönetim

Yönetim kriter kontrolleri 3/4

Vicarious Surgical's CEO'su Adam Sachs, Jan2014 tarihinde atandı, in görev süresi 10.75 yıldır. in toplam yıllık tazminatı $ 3.13M olup, şirket hissesi ve opsiyonları dahil olmak üzere 17.1% maaş ve 82.9% ikramiyelerden oluşmaktadır. şirketin hisselerinin 6.73% ine doğrudan sahiptir ve bu hisseler $ 2.25M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.1 yıl ve 3.1 yıldır.

Anahtar bilgiler

Adam Sachs

İcra Kurulu Başkanı

US$3.1m

Toplam tazminat

CEO maaş yüzdesi	17.1%
CEO görev süresi	10.8yrs
CEO sahipliği	6.7%
Yönetim ortalama görev süresi	3.1yrs
Yönetim Kurulu ortalama görev süresi	3.1yrs

Son yönetim güncellemeleri

Recent updates

Vicarious Surgical: Huge Potential But Low Margin Of Safety To Commercialization

Aug 24

Here's Why We're Watching Vicarious Surgical's (NYSE:RBOT) Cash Burn Situation

Jul 18

Vicarious Surgical: Cash Burn Adds To Downside Risk

May 26

Vicarious Surgical Non-GAAP EPS of -$0.16 beats by $0.02

Feb 13

Vicarious Surgical Non-GAAP EPS of -$0.18 misses by $0.03

Nov 07

Vicarious Surgical Non-GAAP EPS of -$0.16 misses by $0.02

Aug 08

Vectoring In On Vicarious Surgical Inc.

Jun 23

Vicarious Surgical: Developing Minimally Invasive VR Surgical System

Nov 29

CEO Tazminat Analizi

Adam Sachs'un ücretlendirmesi Vicarious Surgical'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$61m
Mar 31 2024	n/a	n/a	-US$61m
Dec 31 2023	US$3m	US$537k	-US$71m
Sep 30 2023	n/a	n/a	-US$69m
Jun 30 2023	n/a	n/a	-US$78m
Mar 31 2023	n/a	n/a	-US$64m
Dec 31 2022	US$5m	US$531k	US$5m
Sep 30 2022	n/a	n/a	US$38m
Jun 30 2022	n/a	n/a	US$18m
Mar 31 2022	n/a	n/a	US$13m
Dec 31 2021	US$6m	US$268k	-US$35m
Sep 30 2021	n/a	n/a	-US$61m
Jun 30 2021	n/a	n/a	-US$19m
Mar 31 2021	n/a	n/a	-US$15m
Dec 31 2020	US$187k	US$180k	-US$13m

Tazminat ve Piyasa: Adam 'nin toplam tazminatı ($USD 3.13M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 677.23K ).

Tazminat ve Kazançlar: Adam 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Adam Sachs (32 yo)

10.8yrs

Görev süresi

US$3,134,667

Tazminat

Mr. Adam David Sachs is Co-Founder at Vicarious Surgical Inc. in 2014. He serves as Chief Executive Officer and Director of Vicarious Surgical Inc. (Formerly, D8 Holdings Corp.) since September 2021. He se...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Adam Sachs	Co-Founder	10.8yrs	US$3.13m	6.73% $ 2.2m
Sammy Khalifa	Co-founder	3.1yrs	US$1.82m	2.83% $ 906.4k
William Kelly	CFO & Treasurer	3.1yrs	US$1.64m	0.013% $ 4.0k
Randolph A. Clark	President	less than a year	Veri yok	Veri yok
Barry Greene	Co-founder & Chief Medical Officer	no data	Veri yok	2.2% $ 704.4k
John Mazzola	Chief Operating Officer	2.8yrs	Veri yok	0.045% $ 14.5k
Erin Checka	Head of Legal & Secretary	no data	Veri yok	Veri yok
Emma Plouffe	Vice President of Business Operations & People	3.1yrs	Veri yok	Veri yok

3.1yrs

Ortalama Görev Süresi

49yo

Ortalama Yaş

Deneyimli Yönetim: RBOT 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.1 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Adam Sachs	Co-Founder	3.1yrs	US$3.13m	6.73% $ 2.2m
Sammy Khalifa	Co-founder	3.1yrs	US$1.82m	2.83% $ 906.4k
Beverly Huss	Independent Director	2yrs	US$196.56k	0.078% $ 24.9k
Ric Fulop	Independent Director	3.1yrs	US$195.77k	0.063% $ 20.3k
David D. Ho	Independent Director	3.1yrs	US$198.45k	0.15% $ 48.6k
Victoria Carr-Brendel	Independent Director	1.8yrs	US$447.60k	0.054% $ 17.2k
Donald F. Tang	Independent Director	3.1yrs	US$185.14k	0.71% $ 227.2k

3.1yrs

Ortalama Görev Süresi

49yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: RBOT 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.1 yıldır).

Vicarious Surgical Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Vicarious Surgical Inc., Annual General Meeting, Jun 10, 2024

Vicarious Surgical Inc. Announces Management Changes

Vicarious Surgical Inc. Announces Appointment of Randy Clark as President Effective, January 29, 2024

Co-Founder recently sold US$54k worth of stock

Co-Founder notifies of intention to sell stock

Vicarious Surgical Inc. Announces Promotion of John Mazzola to Chief Operating Officer

Recent updates

Here's Why Vicarious Surgical (NYSE:RBOT) Must Use Its Cash Wisely

Vicarious Surgical Inc. to Report Q2, 2024 Results on Aug 12, 2024

Price target increased by 21% to US$37.50

Vicarious Surgical Inc., Annual General Meeting, Jun 10, 2024

Vicarious Surgical Inc. to Report Q1, 2024 Results on Apr 29, 2024

New major risk - Revenue and earnings growth

Is Vicarious Surgical (NYSE:RBOT) In A Good Position To Invest In Growth?

Vicarious Surgical Inc. to Report Q4, 2023 Results on Mar 04, 2024

Vicarious Surgical Inc. Announces Management Changes

Vicarious Surgical Inc. Announces Appointment of Randy Clark as President Effective, January 29, 2024

Is Vicarious Surgical (NYSE:RBOT) In A Good Position To Invest In Growth?

Price target decreased by 84% to US$1.13

Vicarious Surgical Inc. to Report Q3, 2023 Results on Nov 13, 2023

New minor risk - Market cap size

Vicarious Surgical Receives Continued Listing Standard Notice From NYSE

Vicarious Surgical Receives Continued Listing Standard Notice From NYSE

Vicarious Surgical: Huge Potential But Low Margin Of Safety To Commercialization

New minor risk - Share price stability

Here's Why We're Watching Vicarious Surgical's (NYSE:RBOT) Cash Burn Situation

Vicarious Surgical Inc. to Report Q2, 2023 Results on Jul 27, 2023

New minor risk - Insider selling

Co-Founder recently sold US$54k worth of stock

Vicarious Surgical: Cash Burn Adds To Downside Risk

Co-Founder notifies of intention to sell stock

Vicarious Surgical Inc. Announces Promotion of John Mazzola to Chief Operating Officer

Insider recently bought US$153k worth of stock

Investor sentiment deteriorates as stock falls 21%

Insider recently bought US$139k worth of stock

Insider recently bought US$78k worth of stock

Co-Founder recently sold US$65k worth of stock

Co-Founder notifies of intention to sell stock

Investor sentiment deteriorates as stock falls 15%

Price target decreased by 21% to US$7.75

Insider recently bought US$241k worth of stock

Vicarious Surgical Non-GAAP EPS of -$0.16 beats by $0.02

Investor sentiment improves as stock rises 17%

Vicarious Surgical Inc. to Report Q4, 2022 Results on Feb 13, 2023

Vicarious Surgical Inc. Announces Changes to Board of Directors

Investor sentiment improved over the past week

Vicarious Surgical Completes Public Demonstration of Beta 2 Surgical Robotic System

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Co-Founder recently sold US$74k worth of stock

High number of new and inexperienced directors

Vicarious Surgical Non-GAAP EPS of -$0.18 misses by $0.03

Investor sentiment improved over the past week

Vicarious Surgical Inc. to Report Q3, 2022 Results on Nov 07, 2022

CFO & Treasurer notifies of intention to sell stock

Vicarious Surgical Inc. Announces Changes to Board of Directors

Independent Director recently sold US$54k worth of stock

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Independent Director recently sold US$87k worth of stock

Vicarious Surgical Non-GAAP EPS of -$0.16 misses by $0.02

Vicarious Surgical Inc. to Report Q2, 2022 Results on Aug 08, 2022

Investor sentiment improved over the past week

Vectoring In On Vicarious Surgical Inc.

Investor sentiment improved over the past week

Independent Director recently sold US$119k worth of stock

Investor sentiment improved over the past week

Independent Director recently sold US$169k worth of stock

High number of new and inexperienced directors

Vicarious Surgical Inc., Annual General Meeting, Jun 01, 2022

Price target decreased to US$11.80

Vicarious Surgical Inc. to Report Q1, 2022 Results on May 09, 2022

Vicarious Surgical Inc. to Report Q4, 2021 Results on Mar 03, 2022

Vicarious Surgical: Developing Minimally Invasive VR Surgical System

No independent directors

CEO Tazminat Analizi